Manas AI

Manas AI is an AI-native biopharmaceutical company engineering a new standard of drug discovery with unprecedented speed, cost-efficiency, and molecular precision. The platform uses neuro-symbolic AI with frontier models built on first principles, codifying deep scientific domain rules from chemistry, physics, and biology. Its end-to-end pipeline spans from target identification to clinical trials, leveraging AI to accelerate every step of bringing medicines to patients. The modality-versatile platform supports discovery across small molecules, antibodies, and siRNA therapies, with a global partnership infrastructure that cuts clinical timelines without compromising patient safety. Manas AI maintains a deep integration with Schrodinger's physics-based AI discovery platform and employs human-in-the-loop expertise to develop only the most viable therapeutic leads. The company targets cancer and rare diseases. Founded in 2025 and headquartered in New York City, Manas AI has raised $50.6M in seed funding from investors including General Catalyst, Greylock Partners, The General Partnership, and Mosaic Ventures.